p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
- PMID: 38762096
- DOI: 10.1016/j.semcancer.2024.05.001
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Abstract
A wealth of evidence has emerged that there is an association between aging, senescence and tumorigenesis. Senescence, a biological process by which cells cease to divide and enter a status of permanent cell cycle arrest, contributes to aging and aging-related diseases, including cancer. Aging populations have the higher incidence of cancer due to a lifetime of exposure to cancer-causing agents, reduction of repairing DNA damage, accumulated genetic mutations, and decreased immune system efficiency. Cancer patients undergoing cytotoxic therapies, such as chemotherapy and radiotherapy, accelerate aging. There is growing evidence that p53/MDM2 (murine double minute 2) axis is critically involved in regulation of aging, senescence and oncogenesis. Therefore, in this review, we describe the functions and mechanisms of p53/MDM2-mediated senescence, aging and carcinogenesis. Moreover, we highlight the small molecular inhibitors, natural compounds and PROTACs (proteolysis targeting chimeras) that target p53/MDM2 pathway to influence aging and cancer. Modification of p53/MDM2 could be a potential strategy for treatment of aging, senescence and tumorigenesis.
Keywords: Aging; Carcinogenesis; MDM2; Senescence; p53.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare no conflict of interest.
Similar articles
-
UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.J Pathol. 2015 Mar;235(4):656-67. doi: 10.1002/path.4478. Epub 2015 Jan 7. J Pathol. 2015. PMID: 25382750
-
Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis.Oncogene. 2017 Mar;36(10):1374-1383. doi: 10.1038/onc.2016.301. Epub 2016 Sep 12. Oncogene. 2017. PMID: 27617574 Free PMC article.
-
MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner.Oncogene. 2019 Apr;38(14):2501-2515. doi: 10.1038/s41388-018-0605-5. Epub 2018 Dec 7. Oncogene. 2019. PMID: 30532073
-
MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.Int J Mol Sci. 2022 Sep 21;23(19):11068. doi: 10.3390/ijms231911068. Int J Mol Sci. 2022. PMID: 36232374 Free PMC article. Review.
-
The RP-Mdm2-p53 pathway and tumorigenesis.Oncotarget. 2011 Mar;2(3):234-8. doi: 10.18632/oncotarget.228. Oncotarget. 2011. PMID: 21406728 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous